Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090025 · ClinicalTrials.gov registry record · Phase 3
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
A Phase 3 study, sponsored by Helsinn Healthcare.
- Terminated
- Registry status
- Phase 3
- Development phase
- 248
- Enrollment target
NCT00090025 is a Phase 3 study that was terminated before completion, run by Helsinn Healthcare. The registered enrollment target is 248 participants.
The verdict
NCT00090025, a Phase 3 study, was terminated before completion, sponsored by Helsinn Healthcare.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 248 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine if XL119 is more effective than the combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of subjects with advanced biliary tumors.
Interventions
- DRUG becatecarin
- DRUG 5-Fluorouracil Plus Leucovorin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090025
The ClinicalTrials.gov registry entry for NCT00090025 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Healthcare, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which becatecarin is the first listed.
NCT00090025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090025 about?
NCT00090025 is a clinical study titled "XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors". The main purpose of this study is to determine if XL119 is more effective than the combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of subjects with advanced biliary tumors.
What is the current status of trial NCT00090025?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 248 participants. The study started on 2004-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00090025?
The interventions under investigation include: becatecarin (DRUG), 5-Fluorouracil Plus Leucovorin (DRUG).
Who is sponsoring clinical trial NCT00090025?
This trial is sponsored by Helsinn Healthcare, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.